Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 405

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 405
---
 Total convertible preferred stock                                                                              |     |      |  42,101,344 |   |     |      |  42,101,344 |   |
| Stockholders’ deficit                                                                                          |     |      |             |   |     |      |             |   |
| Common stock, $0.0001 par value, 45,350,000 shares authorized:                                                 
 9,068,899 and 9,044,733 shares issued and outstanding at December 31, 2023 and 2022, respectively              |     |      |         907 |   |     |      |         904 |   |
| Additional paid-in capital                                                                                     |     |      |   1,031,219 |   |     |      |     928,560 |   |
| Accumulated deficit                                                                                            |     |      | (43,089,821 | ) |     |      | (35,800,244 | ) |
| Total stockholders’ deficit                                                                                    |     |      | (42,057,695 | ) |     |      | (34,870,780 | ) |
| Total liabilities, convertible preferred                                                                       
 stock and stockholders’ deficit                                                                                |     | $    |   5,126,302 |   |     | $    |  11,349,488 |   |

<div align='center'>See accompanying notes to financial
statements.

F-51

CERo Therapeutics, Inc.

Statements of Operations

For the years ended December 31, 2023 and 2022</div>

| Operating expenses:                          |     | 2023 |            |   |     | 2022 |             |   |
|:---------------------------------------------|:----|:-----|-----------:|:--|:----|:-----|------------:|:--|
| Research and development                     |     | $    |  5,288,580 |   |     | $    |   9,845,603 |   |
| General and administrative                   |     |      |  2,386,469 |   |     |      |   2,125,628 |   |
| Total operating expenses                     |     |      |  7,675,049 |   |     |      |  11,971,231 |   |
| Loss from operations                         |     |      | (7,675,049 | ) |     |      | (11,